Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone
Open accessThe DOI matches its Crossref record.
Abstract
Recent observations have shown that the pineal hormone melatonin (MLT) may modulate oestrogen receptor (ER) expression and inhibit breast cancer cell growth. On this basis, we have evaluated the biological and clinical effects of a concomitant MLT therapy in women with metastatic breast cancer who had progressed in response to tamoxifen (TMX) alone. The study included 14 patients with metastasis who did not respond (n = 3) to therapy with TMX alone or progressed after initial stable disease (SD) (n = 11). MLT was given orally at 20 mg day-1 in the evening, every day starting 7 days before TMX, which was given orally at 20 mg day-1 at noon. A partial response was achieved in 4/14 (28.5%) patients (median duration 8 months). The treatment was well tolerated in all cases, and no MLT-induced enhancement of TMX toxicity was seen; on the contrary, most patients experienced a relief of anxiety. Mean serum levels of insulin-like growth factor 1 (IGF-1), which is a growth factor for breast cancer, significantly decreased on therapy, and this decline was significantly higher in responders than in patients with SD or progression. This pilot phase II study would suggest that the concomitant administration of the pineal hormone MLT may induce objective tumour regressions in metastatic breast cancer patients refractory to TMX alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Brzezinski, A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701163360306 · Cited by 1,549
MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective
Liu, J., Clough, S. J., Hutchinson, A. J., Adamah-Biassi, E. B., Popovska-Gorevski, M., & Dubocovich, M. L. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124742 · Cited by 630
Melatonin for the prevention and treatment of cancer
Li, Y., Li, S., Zhou, Y., Meng, X., Zhang, J.-J., Xu, D.-P., & Li, H.-B. (2017) · Oncotarget · doi:10.18632/oncotarget.16379 · Cited by 388
Melatonin receptors in humans: biological role and clinical relevance
Ekmekcioglu, C. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.01.002 · Cited by 370
Melatonin: From Basic Research to Cancer Treatment Clinics
Vijayalaxmi, Thomas, C. R., Reiter, R. J., & Herman, T. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.004 · Cited by 361
Metadata
- Authors
- Lissoni, P., Barni, S., Meregalli, S., Fossati, V, Cazzaniga, M., Esposti, D., & Tancini, G.
- Venue
- British Journal of Cancer
- Published
- 1995-04
- Volume
- 71
- Issue
- 4
- Pages
- 854-856
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1970822477
- Cited by
- 150
- References
- 0
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. https://app.cochat.ai/papers/10.1038/bjc.1995.164
- The paper
- Lissoni, P., Barni, S., Meregalli, S., Fossati, V, Cazzaniga, M., Esposti, D., & Tancini, G. (1995). Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. British Journal of Cancer. https://doi.org/10.1038/bjc.1995.164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.